(Reuters) - The race to create vaccines against the novel coronavirus is entering a critical stretch, with several candidates that were first out of the gate beginning to release late-stage trial data.
Pfizer Inc and its partner BioNTech SE said on Monday their experimental COVID-19 vaccine is more than 90% effective based on initial trial results, a much higher efficacy rate than the 50% minimum required by the U.S. Food and Drug Administration.
Multiple vaccines are likely to make it to market and success will depend on a number of factors, including immune response, safety and distribution.
Reuters is tracking the candidates closest to producing results in this tracker: tmsnrt.rs/36jDuuj
Reporting by Christine Soares, Editing by Tiffany Wu
Our Standards: The Thomson Reuters Trust Principles.